Treatment of mammary tumor-bearing mice with PLX3397 (Pexidartinib), a CSF-1R tyrosine kinase inhibitor, significantly reduced the number of TAMs and resulted in delayed tumor growth stimulated by an increase in CD8 + T cells and a decrease in CD4 + T cells [60]. Here, CSF1R is linked to breast cancer.